- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07828444
New Zealand Blackcurrant and Recovery in Elite Taekwondo (NZBC-TAE)
Effects of New Zealand Blackcurrant Extract Supplementation on Muscle Damage, Oxidative Stress, and Inflammatory Markers Following High-Intensity Training in Elite Taekwondo Athletes
This randomized, double-blind, placebo-controlled trial evaluated the effects of short-term supplementation with anthocyanin-rich New Zealand blackcurrant (NZBC) extract on exercise-induced muscle damage, oxidative stress, antioxidant status, inflammatory responses, and perceived muscle soreness in elite male taekwondo athletes.
Thirty national-level male taekwondo athletes were enrolled and randomly assigned in a 1:1 ratio to receive either NZBC extract (CurraNZ®, UK; 600 mg/day providing approximately 210 mg anthocyanins) or a matched placebo for 7 days. Blood samples and muscle soreness ratings were collected at baseline, immediately after exercise, 24 hours after exercise, and after 7 days.
The primary outcome was plasma creatine kinase (CK). Secondary outcomes included reactive oxygen species (ROS), total antioxidant capacity (TOAC), protein carbonyls, inflammatory cytokines (IL-6, TNF-α, and IL-10), and perceived muscle soreness assessed using a visual analog scale (VAS).
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). Written informed consent was obtained from all participants.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
High-intensity, impact-based sports such as taekwondo involve substantial mechanical and metabolic demands that may contribute to exercise-induced muscle damage, oxidative stress, inflammatory responses, and delayed recovery. Nutritional strategies capable of modulating these physiological responses may therefore be relevant for athletes exposed to repeated high-intensity training.
New Zealand blackcurrant (Ribes nigrum L.) is rich in anthocyanins and other polyphenolic compounds with antioxidant and anti-inflammatory properties. Previous studies involving endurance and intermittent exercise have investigated the potential effects of blackcurrant supplementation on oxidative stress, vascular responses, exercise performance, and recovery. However, evidence in elite combat-sport athletes remains limited.
The objective of this randomized controlled trial was to determine whether 7 days of standardized NZBC extract supplementation influenced biochemical markers of muscle damage, oxidative stress, antioxidant status, inflammatory cytokines, and perceived muscle soreness following repeated high-intensity training in elite male taekwondo athletes.
It was hypothesized that NZBC supplementation would attenuate exercise-associated elevations in plasma creatine kinase and reactive oxygen species, increase total antioxidant capacity, and modulate inflammatory cytokine responses, including IL-6, TNF-α, and IL-10.
The study used a randomized, double-blind, placebo-controlled, parallel-group design and was conducted at the Atik Ali Sports Club in Istanbul, Türkiye, between December 2023 and June 2024. Thirty elite male taekwondo athletes were enrolled and randomly allocated in a 1:1 ratio to receive either NZBC extract or placebo.
Participants assigned to the intervention group received 600 mg/day of New Zealand blackcurrant extract (CurraNZ®, UK), providing approximately 210 mg of anthocyanins, for 7 consecutive days. Participants assigned to the control group received a visually matched maltodextrin placebo. Randomization, allocation concealment, and blinding procedures were maintained throughout the intervention and until database lock.
Blood samples were collected at baseline, immediately following exercise, 24 hours after exercise, and after 7 days. Biochemical outcomes included plasma creatine kinase, reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, and TNF-α. Biomarkers were assessed using commercially available laboratory assay kits. Perceived muscle soreness was evaluated using a visual analog scale. Dietary intake and anthropometric characteristics were also assessed.
The primary outcome was the change in plasma creatine kinase. Secondary outcomes included reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, TNF-α, and perceived muscle soreness.
Statistical analyses were conducted using R version 4.3.1. Data distribution was assessed using the Shapiro-Wilk test, and homogeneity of variance was evaluated using Levene's test. Between-group comparisons were planned using independent-samples t-tests or Mann-Whitney U tests, as appropriate. Longitudinal changes were evaluated using repeated-measures analysis of variance, including group, time, and group × time interaction effects. Greenhouse-Geisser corrections were applied where assumptions of sphericity were not met. Sensitivity analyses were conducted using linear mixed-effects models. Statistical significance was defined as a two-tailed alpha level of 0.05.
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). All participants provided written informed consent before participation.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Tuzla
-
Istanbul, Tuzla, Turchia (Türkiye), 34000
- Okan university
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male national-level taekwondo athletes actively training and competing
- Age between 18 and 35 years
- Free from any chronic disease, metabolic disorder, or recent musculoskeletal injury
- Not using antioxidant, anti-inflammatory, or ergogenic supplements within the last 4 weeks
- Willing to maintain regular diet and training schedule during the study period
- Provided written informed consent
Exclusion Criteria:
- Female athletes
- Presence of chronic illness, injury, or infection
- Use of antioxidant or anti-inflammatory supplements in the 4 weeks prior to enrollment
- Dietary habits incompatible with the intervention (e.g., high anthocyanin intake from other sources)
- Failure to complete all study visits or provide required blood samples
- Withdrawal of consent at any time
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: New Zealand Blackcurrant Extract (NZBC)
Participants received New Zealand blackcurrant extract capsules (CurraNZ®, Healthspan Elite, UK) for 7 days. The daily dose was 600 mg (two 300 mg capsules, morning and evening), providing approximately 210 mg anthocyanins per day. |
Standardized anthocyanin-rich blackcurrant extract administered orally at 600 mg/day (two 300 mg capsules) for 7 consecutive days. Each capsule contained natural polyphenolic compounds standardized to ~35% anthocyanins. |
|
Comparatore placebo: Placebo
Participants received placebo capsules identical in appearance to the NZBC capsules, containing maltodextrin. The placebo was administered orally twice daily for 7 days. |
Two identical capsules containing maltodextrin, taken daily for 7 days (morning and evening), matching the NZBC supplementation schedule. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in plasma Creatine Kinase (CK) concentration
Lasso di tempo: Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Plasma creatine kinase (CK) activity measured via ELISA assay as a biomarker of exercise-induced muscle damage. The outcome represents the change in CK levels from baseline to 24 h and 7 d after repeated high-intensity training sessions. |
Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Reactive Oxygen Species (ROS) levels
Lasso di tempo: Baseline, immediately post-exercise, 24 hours, and 7 days
|
ROS concentrations measured by ELISA to assess oxidative stress response following high-intensity training. |
Baseline, immediately post-exercise, 24 hours, and 7 days
|
|
Change in Total Antioxidant Capacity (TOAC)
Lasso di tempo: Baseline, 24 hours, and 7 days
|
Total antioxidant capacity determined spectrophotometrically using commercial assay kits (Sunredbio, China). Reflects systemic antioxidant defense. |
Baseline, 24 hours, and 7 days
|
|
Change in Inflammatory Cytokines (IL-6, TNF-α, IL-10)
Lasso di tempo: Baseline, 24 hours, and 7 days
|
Serum IL-6, TNF-α, and IL-10 quantified by ELISA to evaluate systemic inflammatory and anti-inflammatory responses to exercise and supplementation. |
Baseline, 24 hours, and 7 days
|
|
Perceived Muscle Soreness (Visual Analog Scale, VAS)
Lasso di tempo: Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Subjective muscle soreness assessed using a 10-cm visual analog scale (VAS), where 0 = no soreness and 10 = extreme soreness. |
Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Hacettepe1234
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data (IPD) that underlie the results reported in this article (deidentified participant data, including baseline characteristics and outcome measures) will be made available upon reasonable request to qualified researchers.
Data will be available after publication of the main results for a period of 3 years.
Requests should be directed to the corresponding author (Assoc. Prof. Sedat Arslan, Bandirma Onyedi Eylul University; email: sarslan@bandirma.edu.tr).
No identifying participant information will be shared. Supporting documents such as the study protocol, statistical analysis plan, and informed consent form will also be provided upon request.
Periodo di condivisione IPD
Deidentified IPD and supporting documents will be available beginning 1 month after publication of the primary results and for 36 months thereafter. If publication is delayed, access will begin 12 months after database lock. Extensions may be granted upon justified request.
Criteri di accesso alla condivisione IPD
Qualified researchers with a methodologically sound proposal may request access by emailing the corresponding author (Assoc. Prof. Sedat Arslan; sarslan@bandirma.edu.tr). Requests must include a brief protocol, objectives, analysis plan, and IRB/ethics determination (if applicable). A data use agreement is required. Only deidentified IPD (baseline characteristics and prespecified outcomes) and documentation (protocol, SAP, ICF templates, analytic code) will be shared. Data will be provided via a secure institutional repository link; re-identification and commercial use are prohibited.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .